Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00800982 · ClinicalTrials.gov registry record · NA

Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis

A NA study of Psoriasis, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT00800982 is a NA study of Psoriasis that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00800982, a NA study of Psoriasis, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This is a single-center, open-label, pilot study. A total of 30 subjects (15 in each study arm) will be enrolled in this 6 month study to evaluate whether the addition of narrow band UVB (NB-UVB) phototherapy can enhance the efficacy of etanercept's maintenance dose, 50 mg once a week, in obese psoriasis patients.

Conditions Studied

Interventions

  • PROCEDURE Narrow band (310-312 nm) ultraviolet light B phototherapy
  • DRUG etanercept

Study Locations (1)

California

  • UCSF Psoriasis and Skin Treatment Center - San Francisco

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-10
Est. Completion 2012-03
Phase NA

What the Registry Record Tells You About NCT00800982

The ClinicalTrials.gov registry entry for NCT00800982 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Narrow band (310-312 nm) ultraviolet light B phototherapy is the first listed.

NCT00800982 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00800982 about?

NCT00800982 is a clinical study titled "Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis". This is a single-center, open-label, pilot study. A total of 30 subjects (15 in each study arm) will be enrolled in this 6 month study to evaluate whether the addition of narrow band UVB (NB-UVB) phototherapy can enhance the efficacy of etanercept's maintenance dose, 50 mg once a week, in obese psor...

What is the current status of trial NCT00800982?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2008-10. Estimated completion is 2012-03.

What conditions does trial NCT00800982 study?

This clinical trial studies the following conditions: Psoriasis.

What interventions are being tested in trial NCT00800982?

The interventions under investigation include: Narrow band (310-312 nm) ultraviolet light B phototherapy (PROCEDURE), etanercept (DRUG).

Who is sponsoring clinical trial NCT00800982?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00800982 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Psoriasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.